NCT01488097View on ClinicalTrials.gov

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

June 21, 2017

Study Completion Date

June 21, 2017

Conditions
Cholesterol Ester Storage Disease (CESD)Lysosomal Acid Lipase DeficiencyLAL-Deficiency
Interventions
DRUG

sebelipase alfa

Sebelipase alfa is a recombinant human lysosomal acid lipase.

Trial Locations (10)

10029

New York

55455

Minneapolis

94143

San Francisco

95817

Sacramento

95501-320

Eureka

Unknown

Greater Sudbury

Prague

Paris

Leeds

Salford

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY